296 related articles for article (PubMed ID: 20931330)
1. Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?
Magliulo L; Dahl ML; Lombardi G; Fallarini S; Villa LM; Biolcati A; Scordo MG
Eur J Clin Pharmacol; 2011 Jan; 67(1):47-54. PubMed ID: 20931330
[TBL] [Abstract][Full Text] [Related]
2. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
3. Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease.
Coin A; Pamio MV; Alexopoulos C; Granziera S; Groppa F; de Rosa G; Girardi A; Sergi G; Manzato E; Padrini R
Eur J Clin Pharmacol; 2016 Jun; 72(6):711-7. PubMed ID: 26952092
[TBL] [Abstract][Full Text] [Related]
4. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
6. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.
Genvigir FD; Salgado PC; Felipe CR; Luo EY; Alves C; Cerda A; Tedesco-Silva H; Medina-Pestana JO; Oliveira N; Rodrigues AC; Doi SQ; Hirata MH; Hirata RD
Pharmacogenet Genomics; 2016 Oct; 26(10):462-72. PubMed ID: 27434656
[TBL] [Abstract][Full Text] [Related]
7. Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease.
Sonali N; Tripathi M; Sagar R; Velpandian T; Subbiah V
Dement Geriatr Cogn Disord; 2014; 37(1-2):58-70. PubMed ID: 24107805
[TBL] [Abstract][Full Text] [Related]
8. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
[TBL] [Abstract][Full Text] [Related]
9. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.
Fiegenbaum M; da Silveira FR; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
Clin Pharmacol Ther; 2005 Nov; 78(5):551-8. PubMed ID: 16321621
[TBL] [Abstract][Full Text] [Related]
10. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
Qiu F; He XJ; Sun YX; Li-Ling J; Zhao LM
Pharmacol Rep; 2011; 63(3):815-25. PubMed ID: 21857093
[TBL] [Abstract][Full Text] [Related]
11. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
Gunes A; Spina E; Dahl ML; Scordo MG
Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
Bouamar R; Hesselink DA; van Schaik RH; Weimar W; Macphee IA; de Fijter JW; van Gelder T
Ther Drug Monit; 2011 Apr; 33(2):178-84. PubMed ID: 21383650
[TBL] [Abstract][Full Text] [Related]
13. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.
Turolo S; Tirelli AS; Ferraresso M; Ghio L; Belingheri M; Groppali E; Torresani E; Edefonti A
Pharmacol Rep; 2010; 62(6):1159-69. PubMed ID: 21273673
[TBL] [Abstract][Full Text] [Related]
14. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients.
Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Biondi F; Sanguedolce R; Vizzini G; Palazzo U; Polidori P; Triolo F; Gridelli B; D'Alessandro N
Ann Transplant; 2009; 14(1):23-31. PubMed ID: 19289993
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer.
Ozeki T; Nagahama M; Fujita K; Suzuki A; Sugino K; Ito K; Miura M
Sci Rep; 2019 Apr; 9(1):5404. PubMed ID: 30931962
[TBL] [Abstract][Full Text] [Related]
16. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
[TBL] [Abstract][Full Text] [Related]
17. ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients.
Lee J; Huang H; Chen Y; Lu X
Biopharm Drug Dispos; 2014 Apr; 35(3):164-72. PubMed ID: 24285256
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2D6, CYP3A5, and ABCB1 Polymorphisms on Plasma Concentrations of Donepezil and Its Metabolite in Patients With Alzheimer Disease.
Kagawa Y; Yamamoto Y; Ueno A; Maeda T; Obi T
Ther Drug Monit; 2021 Jun; 43(3):429-435. PubMed ID: 33065613
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.
Noetzli M; Guidi M; Ebbing K; Eyer S; Wilhelm L; Michon A; Thomazic V; Stancu I; Alnawaqil AM; Bula C; Zumbach S; Gaillard M; Giannakopoulos P; von Gunten A; Csajka C; Eap CB
Br J Clin Pharmacol; 2014 Jul; 78(1):135-44. PubMed ID: 24433464
[TBL] [Abstract][Full Text] [Related]
20. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
Ganoci L; Trkulja V; Živković M; Božina T; Šagud M; Lovrić M; Božina N
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110042. PubMed ID: 32682874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
